CA2766656A1 - Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms - Google Patents

Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms Download PDF

Info

Publication number
CA2766656A1
CA2766656A1 CA2766656A CA2766656A CA2766656A1 CA 2766656 A1 CA2766656 A1 CA 2766656A1 CA 2766656 A CA2766656 A CA 2766656A CA 2766656 A CA2766656 A CA 2766656A CA 2766656 A1 CA2766656 A1 CA 2766656A1
Authority
CA
Canada
Prior art keywords
cancer
macroh2a2
expression
tumor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2766656A
Other languages
English (en)
French (fr)
Inventor
Andreas Ladurner
Judith Sporn
Thomas Muley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THORAXKLINIK-HEIDELBERG GGMBH
Europaisches Laboratorium fuer Molekularbiologie EMBL
Original Assignee
THORAXKLINIK-HEIDELBERG GGMBH
Europaisches Laboratorium fuer Molekularbiologie EMBL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THORAXKLINIK-HEIDELBERG GGMBH, Europaisches Laboratorium fuer Molekularbiologie EMBL filed Critical THORAXKLINIK-HEIDELBERG GGMBH
Publication of CA2766656A1 publication Critical patent/CA2766656A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2766656A 2009-07-02 2010-07-02 Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms Abandoned CA2766656A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09008679A EP2270510A1 (en) 2009-07-02 2009-07-02 Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
EP09008679.4 2009-07-02
PCT/EP2010/004008 WO2011000573A1 (en) 2009-07-02 2010-07-02 Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms

Publications (1)

Publication Number Publication Date
CA2766656A1 true CA2766656A1 (en) 2011-01-06

Family

ID=41100520

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2766656A Abandoned CA2766656A1 (en) 2009-07-02 2010-07-02 Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms

Country Status (11)

Country Link
US (1) US20120171225A1 (https=)
EP (2) EP2270510A1 (https=)
JP (1) JP5792165B2 (https=)
CN (1) CN102472753B (https=)
AU (1) AU2010268389B2 (https=)
BR (1) BRPI1011925A2 (https=)
CA (1) CA2766656A1 (https=)
ES (1) ES2681687T3 (https=)
SG (1) SG177398A1 (https=)
WO (1) WO2011000573A1 (https=)
ZA (1) ZA201109381B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201604806D0 (en) * 2016-03-22 2016-05-04 Singapore Volition Pte Ltd Method of identifying a cancer of unknown origin
EP3508855A1 (en) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Method for the selection of patients and kit
EP3546944A1 (en) * 2018-03-30 2019-10-02 Universite d'Aix-Marseille (AMU) Diagnosis and treatment of a cancer based on the overexpression of the adamtsl5 gene
CN108957004B (zh) * 2018-07-09 2021-10-19 东南大学 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN111896740B (zh) * 2019-05-06 2025-02-11 山东大学 诊断或预测生育缺陷的试剂盒
CN119736252B (zh) * 2025-01-15 2025-06-27 首都医科大学 组蛋白变体macroH2A调控巨噬细胞功能在改善肿瘤免疫微环境中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2197915B (en) 1986-11-19 1990-11-14 Rolls Royce Plc Improvements in or relating to fluid bearings
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030190640A1 (en) * 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20050085628A1 (en) * 2002-01-31 2005-04-21 Kinya Yoda Production of hybridoma producing antihuman cenp-a peptide monoclonal antibody and method of using the same
DE60200248T2 (de) * 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
CN100480382C (zh) * 2002-08-16 2009-04-22 抗癌公司 实时测量细胞反应
WO2004063355A2 (en) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
EP1640452A4 (en) * 2003-05-30 2009-12-23 Nippon Shinyaku Co Ltd OLIGOBICATENARY RNA INHIBITING BCL-2 EXPRESSION AND MEDICINAL COMPOSITION CONTAINING THE SAME
EP1682904A2 (en) * 2003-11-04 2006-07-26 Roche Diagnostics GmbH Method for distinguishing who classified aml subtypes
DE102004037860A1 (de) * 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
WO2006119435A2 (en) * 2005-05-04 2006-11-09 Invitrogen Corporation Identification of cancer biomarkers and phosphorylated proteins
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
EP1948215B1 (en) * 2005-11-14 2012-01-11 Centre National De La Recherche Scientifique (Cnrs) MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof
EP2145021A2 (en) * 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
JP2008292424A (ja) * 2007-05-28 2008-12-04 Nippon Medical School 腫瘍の検出方法
EP2185728A2 (en) * 2007-09-07 2010-05-19 Université Libre de Bruxelles Methods and tools for prognosis of cancer in er- patients
US20110224313A1 (en) * 2008-06-05 2011-09-15 British Columbia Cancer Agency Branch Compositions and methods for classifying lung cancer and prognosing lung cancer survival

Also Published As

Publication number Publication date
AU2010268389B2 (en) 2014-09-11
EP2449383A1 (en) 2012-05-09
AU2010268389A1 (en) 2012-01-19
JP2012531612A (ja) 2012-12-10
AU2010268389A2 (en) 2012-01-12
EP2270510A1 (en) 2011-01-05
ES2681687T3 (es) 2018-09-14
WO2011000573A1 (en) 2011-01-06
ZA201109381B (en) 2012-08-29
CN102472753A (zh) 2012-05-23
EP2449383B1 (en) 2018-05-16
US20120171225A1 (en) 2012-07-05
BRPI1011925A2 (pt) 2017-10-10
JP5792165B2 (ja) 2015-10-07
SG177398A1 (en) 2012-02-28
CN102472753B (zh) 2015-02-11

Similar Documents

Publication Publication Date Title
De Petris et al. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer
AU2010268389B2 (en) Diagnostic method for predicting the risk of cancer recurrence based on histone macroH2A isoforms
CA2712204A1 (en) Small cell lung carcinoma biomarker panel
US20120052071A1 (en) Tumor markers and methods of use thereof
JP2012524278A (ja) がんの臨床診断および予後診断のためのヒストン修飾パターン
EP2473621B1 (en) Methods for detection of lethal cell and uses thereof
Bian et al. Rac GTPase activating protein 1 promotes gallbladder cancer via binding DNA ligase 3 to reduce apoptosis
JP2013543117A (ja) Ｂｒａｆｖ６００ｅに特異的に結合する抗体を使用する癌の診断のための手段及び方法
WO2012044921A1 (en) Methods and compositions for typing molecular subgroups of medulloblastoma
Hua et al. LOX expression in primary nasopharyngeal carcinoma: correlation with prognostic parameters and outcome
CN103180455B (zh) 侦测致死系统的方法及其用途
US9182404B2 (en) Tumor markers and methods of use thereof
AU2013359398B2 (en) Methods for diagnosing and treating prostate cancer
JP2021019612A (ja) 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法
Zhou et al. HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas
JP2022153482A (ja) 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ
WO2010123124A1 (ja) 固形がんの再発および予後因子、およびその臨床利用
JP2017108686A (ja) 膵癌の再発リスクの予測に用いるための診断薬及びキット、並びに予測方法
HK1170569B (en) Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms
HK1170569A (en) Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms
ES2743508T3 (es) Métodos y productos para el diagnóstico y el pronóstico de la malignidad de tumores de ovario
JP2015021800A (ja) 腎癌の再発リスクの予測に用いるための診断薬及びキット、並びに予測方法
유윤종 Analysis of Clinical Prognostic Significance of Cancer Stem Cell Markers in Patients with Papillary Thyroid Carcinoma
Sun et al. Functional screen for secreted proteins by monoclonal antibody library and
WO2019021654A1 (ja) 膵癌の予後マーカー、膵癌の予後診断キット及び膵癌の予後を予測するための方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150609

FZDE Discontinued

Effective date: 20210831